India approval opens door to a US$700 million nerve repair market
ReNerve (ASX:RNV) has secured marketing approval for its NervAlign® Nerve Cuff in India, granted by the country’s Central Drugs Standard Control Organisation (CDSCO). The approval marks the company’s first product approval in the Indian market, a major milestone for the Australian biotechnology firm.
The clearance opens the way for commercial supply of the device and delivers the first key objective of ReNerve’s partnership with its Indian commercialisation partner, NetCentrix Ventures.
India represents one of the largest opportunities in ReNerve’s global commercialisation strategy. The Indian nerve repair and regeneration market was valued at approximately USD $700 million in 2025, underpinned by a population of over 1.45 billion people and one of the world’s highest burdens of road trauma.
When big ASX news breaks, our subscribers know first
What the CDSCO approval unlocks
The registration approval clears the path for the commercial rollout of the NervAlign® Nerve Cuff across India. ReNerve and NetCentrix are now progressing a coordinated commercialisation strategy tailored to the Indian healthcare ecosystem.
Groundwork is already underway. To date, the two companies have been working within India to identify customers and progress hospital approval processes.
NetCentrix Ventures is a commercialisation specialist in the Indian healthcare market, providing ReNerve with local regulatory expertise and established distribution networks. The company also holds a Memorandum of Understanding with BRIC-RGCB, an institution of the Biotechnology Research and Innovation Council under the Government of India’s Department of Biotechnology.
ReNerve entered its agreement with NetCentrix Ventures in April 2025 to pursue regulatory approval and commercialisation of the NervAlign® Nerve Cuff in India.
Dr Julian Chick, CEO of ReNerve
“Securing marketing approval in India is a landmark milestone for ReNerve. India is the world’s most populous country and one of the largest and fastest-growing healthcare markets globally, and the clinical need for effective peripheral nerve repair, driven by significant number of trauma cases, is enormous.”
Why India is a major opportunity for ReNerve
India’s demographic and clinical profile points to substantial and growing demand for peripheral nerve repair solutions. The key drivers include:
-
Population scale – over 1.45 billion people, representing a very large and rapidly expanding addressable patient population.
-
Trauma burden – India records the highest number of road-traffic deaths of any country in the world, more than 150,000 fatalities each year, with far larger numbers of serious injuries.
-
Two-wheelers account for a substantial share of casualties, making road trauma a major cause of traumatic peripheral nerve damage and severe limb injury.
-
Market value – approximately USD $700 million in 2025, according to Grand View Research.
For investors, the approval provides access to a large, addressable market that feeds directly into ReNerve’s broader global commercialisation strategy.
The Indonesian market entry, secured in July 2026, demonstrated the same structural demand thesis at work across the region: a population exceeding 280 million people, a high road-traffic death toll, and two-wheelers as the dominant vehicle class driving peripheral nerve injury rates.
Understanding peripheral nerve repair
Peripheral nerve injury (PNI) is often caused by road trauma and requires an ideal healing environment for repair and regeneration.
The NervAlign® Nerve Cuff addresses this challenge. It is a bioabsorbable protective wrap that is naturally absorbed within six months of surgery.
Clinical evidence supports the product’s benefit. A US clinical study reported that patients treated with the device experienced post-surgical pain scores dropping from 7.1 to 0.4, compared with 7.1 to 3.3 where the device was not used, a statistically significant improvement.
| Measure | With NervAlign® | Standard of Care | Improvement | Investor takeaway |
|---|---|---|---|---|
| Post-surgical pain score (from 7.1 baseline) | 0.4 | 3.3 | 96% vs 54% | Statistically significant clinical differentiation supporting adoption |
The NervAlign® Nerve Cuff is FDA-cleared and already in use across the United States.
The investment case and what comes next
The India approval connects to a broader growth story for ReNerve. Supporting context includes:
-
53% revenue growth in FY25, reaching $271k in sales, with YTD FY2026 sales showing further significant increases across the portfolio.
-
The global nerve repair market was valued at US$1.6 billion in 2024 and is projected to reach US$6.2 billion by 2031.
-
A broader product portfolio spanning the NervAlign® Nerve Cuff, Empliq™ deep dermal and amniotic tissue ranges currently on market, with the NervAlign® Nerve Conduit, Nerve Guide Matrix and Bionic Nerve in development.
The next step is progressing the coordinated commercial rollout across India alongside NetCentrix. No specific India revenue forecast or rollout timeline has been disclosed.
With regulatory clearance now secured in one of the world’s largest healthcare markets, the India approval marks a further step in ReNerve’s global commercialisation strategy for peripheral nerve repair.
For readers wanting to understand what sits behind the NervAlign commercial franchise beyond the Nerve Cuff, our full explainer on the NervAlign Nerve Guide Matrix covers the four-stage production process underway ahead of FDA submission and the unmet clinical need the product targets.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ active subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.